GlaxoSmithKline is touting stellar Phase III results for an in-development combo therapy for melanoma, saying its treatment beat out Roche’s Zelboraf in overall survival and led independent advisers to recommend an early end for the study.

…read more

Source: GlaxoSmithKline’s melanoma combo beats Roche’s Zelboraf in Phase III


0 No comments